Streetbeat News

Regulatory

MOTS

Motus GI has received FDA clearance to commercialize its Pure-Vu EVS Gastro and Gen 4 Colon products. This approval could potentially boost the company's market presence and revenue.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:11 pm

TSHA

Taysha Gene Therapies has presented new preclinical in-vitro data on TSHA-102 in Rett Syndrome at the European Society of Gene & Cell Therapy 30th Annual Congress. The data showed that the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models. Clinical data from two adult patients dosed with TSHA-102 will be reported in mid-November, and the first pediatric Rett syndrome patient is expected to be dosed in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:10 pm

NKGN

NKGen Biotech has received FDA clearance for its Investigational New Drug application for SNK01 NK cell therapy to treat Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:10 pm

IMMP

Immutep has reported promising efficacy and tolerability from its INSIGHT-003 trial at the ESMO Congress 2023. The trial involved efti plus anti-PD-1 therapy and doublet chemotherapy as first-line therapy in metastatic non-squamous non-small cell lung cancer. The trial showed a 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median Progression Free Survival, and median Overall Survival that has not been reached.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:09 pm

RNAZ

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced preliminary results from its Phase 0 clinical trial of its lead therapeutic candidate, TTX-MC138, for treating metastatic cancer. The data showed that TTX-MC138 was successfully delivered to metastatic lesions and had pharmacokinetic behavior consistent with non-clinical IND-enabling studies. The patient tolerated the dosing with no reported adverse reactions. The trial is not intended to demonstrate a therapeutic effect but to inform dose selection and frequency for further clinical development.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:07 pm

RYZB

The FDA has selected RayzeBio to participate in its inaugural CDRP program, aimed at expediting commercial manufacturing readiness for RYZ101 in GEP-NETs.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:05 pm

UNH

UnitedHealthcare, a division of UnitedHealth Group (UNH), announced it will offer individual and family plans on the Health Insurance Marketplace in 26 states for 2024. The plans will include benefits such as $0 unlimited primary and virtual urgent care, prescriptions as low as $5, dental and vision coverage, and up to $100 in reward incentives. The company is expanding its ACA Marketplace offerings into four new states: New Jersey, New Mexico, South Carolina, and Wisconsin.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:04 pm

NKLA

An arbitration panel in New York has awarded Nikola Corporation approximately $165M plus interest, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 12:04 pm

BTCUSD

GBTC

Peter Schiff, a gold investor, has warned that the current Bitcoin rally could peak if the Grayscale Bitcoin Trust (GBTC) is approved to convert into an ETF by the SEC. He suggests that a potential selloff could occur if this conversion takes place. This comes as the SEC and Grayscale's dispute over the approval of a spot bitcoin ETF has concluded, with the D.C. Circuit Court of Appeals directing the SEC to abandon its rejection of Grayscale's application.

Portfolio Pulse from Mehab Qureshi

October 24, 2023 | 12:00 pm

TSLA

Tesla's former CFO Zachary Kirkhorn may have been fired rather than resigned, according to Future Fund Managing Partner and Tesla investor Gary Black. This speculation is based on a severance agreement found in Tesla's third-quarter earnings report. The severance agreement suggests termination rather than resignation. The reason for the potential firing could be disagreement on pricing philosophy, as Tesla has been aggressively cutting prices, leading to margin erosion and a double miss in the third quarter.

Portfolio Pulse from Shanthi Rexaline

October 24, 2023 | 11:52 am